Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
17 sept. 2020 07h00 HE
|
Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors – – Masked prodrug...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
17 sept. 2020 06h30 HE
|
Checkpoint Therapeutics, Inc
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohortInterim results presented at ESMO Virtual Congress 2020On track to report full top-line results in...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
15 sept. 2020 07h18 HE
|
Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
08 sept. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
26 août 2020 18h05 HE
|
Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
Immunoscore included in ESMO Clinical Practice Guidelines 2020
06 août 2020 07h45 HE
|
HalioDx
Immunoscore® included in ESMO Clinical Practice Guidelines 2020 Marseille, France, August 06, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been...
BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
05 août 2020 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
12 déc. 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockadeIndependent safety profiles of PV-10 and checkpoint inhibition were...
Provectus Announces Acceptance of PV-10® Poster Presentations at ESMO Immuno-Oncology Congress 2019
24 oct. 2019 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal...
New Data Presented on ASLAN’s varlitinib at ESMO 2019
02 oct. 2019 02h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...